Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 8/20 | 0.60 |
| ▸ | DYRK1B | Q9Y463 | 8/20 | 0.60 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.58 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.58 |
| ▸ | KMO | O15229 | 2/20 | 0.55 |
| ▸ | ALAD | P13716 | 2/20 | 0.53 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | CLK1 | P49759 | 1/20 | 0.46 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.46 |
| ▸ | PIM1 | P11309 | 1/20 | 0.46 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27605086 | 0.89 | DYRK1A (0.62) | DYRK1ADYRK1BMKNK1MKNK2KMO | |
| SCHEMBL7127091 | 0.86 | DYRK1B (0.58) | DYRK1ADYRK1BMKNK1MKNK2KMO | |
| SCHEMBL4381926 | 0.81 | ALAD (0.66) | ALADHDAC6 | |
| SCHEMBL505511 | 0.81 | ALAD (0.70) | KMOALADNPC1RAB9AHDAC6 | |
| SCHEMBL6143622 | 0.80 | ALAD (0.69) | ALADHDAC6 | |
| SCHEMBL16087219 | 0.79 | MARK3 (0.70) | DYRK1AMKNK2PIM1 | |
| Hydrochloric Acid SCHEMBL3763532 | 0.78 | MARK3 (0.69) | DYRK1AMKNK2PIM1 | |
| SCHEMBL1761887 | 0.77 | ALAD (0.59) | KMOALADRAB9AHDAC6 | |
| SCHEMBL6852049 | 0.76 | DYRK1A (0.54) | DYRK1ADYRK1BDYRK2ALDH1A1CYP1A2 | |
| SCHEMBL6852045 | 0.76 | DYRK1A (0.54) | DYRK1ADYRK1BDYRK2ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250145597-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | ACCENT THERAPEUTICS, INC. | 2025-05-08 | — | — | US | disclosed |
| CN-119923385-A | Inhibitors of RNA helicase DHX9 and uses thereof | 埃克森特治疗公司 | 2025-05-02 | — | — | CN | disclosed |
| US-12233065-B2 | Inhibitors of RNA helicase DHX9 and uses thereof | ACCENT THERAPEUTICS, INC. (US) | 2025-02-25 | — | — | US | disclosed |
| EP-4479138-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | Accent Therapeutics, Inc. (US) | 2024-12-25 | — | — | EP | disclosed |
| US-12162867-B2 | Inhibitors of RNA helicase DHX9 and uses thereof | ACCENT THERAPEUTICS, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| US-20240316047-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | ACCENT THERAPEUTICS, INC. | 2024-09-26 | — | — | US | disclosed |
| US-20240279210-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | ACCENT THERAPEUTICS, INC. | 2024-08-22 | — | — | US | disclosed |
| WO-2023154519-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | ACCENT THERAPEUTICS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023154519-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | ACCENT THERAPEUTICS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| EP-0931060-B1 | SUBSTITUTED N- (AMINOIMINOMETHYL OR AMINOMETHYL)PHENYL PROPYL AMIDES | AVENTIS PHARMA INC (US) | 2009-11-25 | — | — | EP | disclosed |
| CN-1221529-C | Substituted N- [ (aminoiminomethyl or aminomethyl) phenyl ] propyl amides | ARVENTIS PHARMACEUTICALS INC (US) | 2005-10-05 | — | — | CN | disclosed |
| EP-0931060-A4 | SUBSTITUTED N- (AMINOIMINOMETHYL OR AMINOMETHYL)PHENYL]PROPYL AMIDES | AVENTIS PHARMA INC (US) | 2004-10-06 | — | — | EP | disclosed |
| US-20040138250-A1 | Inhibitors of cruzipain and other cysteine proteases | GRUNENTHAL GMBH (DE) | 2004-07-15 | — | — | US | disclosed |
| US-20040127549-A1 | Cyclic 2-carbonylaminoketones as inhibitors of cruzipain and other cysteine proteases | AMURA THERAPEUTICS LIMITED (GB) | 2004-07-01 | — | — | US | disclosed |
| EP-1362052-A1 | INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | Amura Therapeutics Limited (GB) | 2003-11-19 | — | — | EP | disclosed |
| WO-2002057270-A1 | INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | AMURA THERAPEUTICS LIMITED (GB) | 2002-07-25 | — | — | WO | disclosed |
| US-6323227-B1 | PRODRUGS | AVENTIS PHARMACEUTICALS PRODUCTS INC. | 2001-11-27 | — | — | US | disclosed |
| CN-1236358-A | Substituted N-[(aminoiminomethyl or aminomethyl) phenyl] propyl amides | RHONE POULENC RORER PHARMA (US) | 1999-11-24 | — | — | CN | disclosed |
| EP-0931060-A1 | SUBSTITUTED N- (AMINOIMINOMETHYL OR AMINOMETHYL)PHENYL]PROPYL AMIDES | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1999-07-28 | — | — | EP | disclosed |
| WO-1999000356-A1 | SUBSTITUTED N-[(AMINOIMINOMETHYL OR AMINOMETHYL)PHENYL]PROPYL AMIDES | RHÔNE-POULENC RORER PHARMACEUTICALS INC. (US) | 1999-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240316047-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | DHX29, DHX9, DDX39B | DYRK1A 3529/4885DYRK1B 2993/4885MKNK1 2447/4885 |
| US-20040127549-A1 | Cyclic 2-carbonylaminoketones as inhibitors of cruzipain and other cysteine proteases | CPN1, CTRL, CPA1 | DYRK1A 2906/4885DYRK1B 3184/4885MKNK1 240/4885 |
| US-20240279210-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | DHX29, DHX9, DDX39B | DYRK1A 3794/4885DYRK1B 3618/4885MKNK1 2551/4885 |
| US-20040138250-A1 | Inhibitors of cruzipain and other cysteine proteases | CPN1, CTRL, CPA1 | DYRK1A 4129/4885DYRK1B 4173/4885MKNK1 2199/4885 |
| US-12233065-B2 | Inhibitors of RNA helicase DHX9 and uses thereof | DHX29, DHX9, DDX39B | DYRK1A 3529/4885DYRK1B 2993/4885MKNK1 2447/4885 |
| US-12162867-B2 | Inhibitors of RNA helicase DHX9 and uses thereof | DHX29, DHX9, DDX39B | DYRK1A 3794/4885DYRK1B 3618/4885MKNK1 2551/4885 |
| US-20250145597-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | DHX9, DHX29, DDX39B | DYRK1A 3618/4885DYRK1B 3743/4885MKNK1 2310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.